Quellenangaben

Quellenangaben zu: Weiterführende Hinweise zur Impfung mit dem Impfstoff AZD1222 (COVID-19 Vaccine AstraZeneca ®) der Firma AstraZeneca AB

 

Der Impfstoff wird nicht für ältere Menschen empfohlen, weil Studiendaten fehlen.

EMA/AstraZeneca: Summary Of Product Characteristics COVID-19 Vaccine AstraZeneca, Stand 29. Jan. 2021;
https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-epar-product-information_en.pdf

Medicines & Healthcare Products Regulatory Agendy: Public Assessment Report COVID-19 Vaccine AstraZeneca, 5. Jan. 2021;
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf

Empfehlung der Ständigen Impfkommission (STIKO) vom 04. Februar 2021 STIKO: Epidemiol. Bull. 2021; Nr. 5: 3-79;
https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/05_21.pdf

 

Der Impfstoff ist vergleichbar zu anderen, wenn es um schwere Covid-19-Verläufe geht.

EMA/AstraZeneca: Summary Of Product Characteristics COVID-19 Vaccine AstraZeneca, Stand 29. Jan. 2021;
https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-epar-product-information_en.pdf

Medicines & Healthcare Products Regulatory Agendy: Public Assessment Report COVID-19 Vaccine AstraZeneca, 5. Jan. 2021;
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf

Voysey, M. et al.: Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine; Lancet Preprint, online publiziert am 01. Februar 2021;
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268

 

Der Impfstoff aktiviert das Immunsystem im hohen Maße – auch wenn’s wehtut.

EMA/AstraZeneca: Summary Of Product Characteristics COVID-19 Vaccine AstraZeneca, Stand 29. Jan. 2021;
https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-epar-product-information_en.pdf

Medicines & Healthcare Products Regulatory Agendy: Public Assessment Report COVID-19 Vaccine AstraZeneca, 5. Jan. 2021;
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf

Sicherheitsbericht des Paul-Ehrlich-Institutes vom 18. Februar 2021
https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-12-02-21.pdf

Folegatti P.M. et al, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial; The Lancet 2020, 396, 467-478;
https://www.sciencedirect.com/science/article/pii/S0140673620316044

Ramasamy M.A. et al, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial; The Lancet 2020, 396, 1979-1993;
https://www.sciencedirect.com/science/article/pii/S0140673620324661

 

Der Impfstoff kann die Zahl der Übertragungen reduzieren.

Voysey, M. et al.: Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine; Lancet Preprint, online publ. am 1. Febr. 2021;
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268

Voysey, M. et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK“; Lancet 2021; 397: 99-111;
https://doi.org/10.1016/S0140-6736(20)32661-1

Einschätzung des Arznei-Telegramms vom 19. Februar 2021;
https://www.arznei-telegramm.de/html/2021_02/2102009_02.html

 

Der Impfstoff hat eine vergleichbare Wirksamkeit gegen die „britische Mutation“.

Emary, K.R.W. et al.: Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) ; Lancet Preprint, online publiziert am 04. Februar 2021;
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160

Madhi, S.A. et al.: Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa; medRxiv (Preprint), 12. Februar 2021;
https://doi.org/10.1101/2021.02.10.21251247